SAMSMON: A Potential Drug Target and Biomarker (G101927152)

Target Name: SAMMSON

NCBI ID: G101927152

SAMMSON

Other Name(s): LINC01212 | Survival associated mitochondrial melanoma specific oncogenic non-coding RNA | survival associated mitochondrial melanoma specific oncogenic non-coding RNA

SAMSMON: A Potential Drug Target and Biomarker

SAMSMON is a protein that is expressed in various tissues of the body, including the brain, pancreas, and muscle. It is a key regulator of the immune response and has been implicated in a number of diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. In recent years, researchers have been investigating the potential therapeutic benefits of targeting SAMSMON as a drug target.

SAMSMON functions as a negative regulator of the T-cell receptor, which is a critical receptor that helps coordinate the immune response. When the T-cell receptor is activated, SAMSMON is recruited to the receptor and works to inhibit its activity. This process is important for maintaining the immune response, but it can also contribute to the development of autoimmune disorders and cancer.

SAMSMON has also been shown to play a role in the regulation of pancreatic cancer. Studies have shown that high levels of SAMSMON are associated with poor prognosis in pancreatic cancer patients. Additionally, SAMSMON has been shown to promote the growth and survival of pancreatic cancer cells in cell culture. These findings suggest that targeting SAMSMON may be a promising strategy for the development of new treatments for pancreatic cancer.

Another potential application of SAMSMON as a drug target is its role in the regulation of neurodegenerative diseases. SAMSMON has been shown to interact with a number of neurotransmitters, including dopamine, and has been implicated in the regulation of movement and motor function. Additionally, SAMSMON has been shown to protect against neurotoxins, which can cause neurodegenerative diseases. These findings suggest that targeting SAMSMON may be a promising strategy for the development of new treatments for neurodegenerative diseases.

In addition to its potential therapeutic applications, SAMSMON is also a potential biomarker for a number of diseases. SAMSMON is expressed in a number of tissues and has been shown to be involved in the regulation of a wide range of physiological processes. This makes it an attractive candidate for use as a biomarker for a number of diseases. For example, SAMSMON has been shown to be involved in the regulation of inflammation, and high levels of SAMSMON have been associated with an increased risk of inflammatory diseases. Additionally, SAMSMON has been shown to be involved in the regulation of blood pressure and has been shown to be involved in the development of cardiovascular disease. These findings suggest that SAMSMON may be a valuable biomarker for a number of diseases.

In conclusion, SAMSMON is a protein that has been shown to play a number of important roles in various physiological processes in the body. Its functions as a negative regulator of the T-cell receptor, its role in the regulation of pancreatic cancer, and its potential as a drug target and biomarker make it an attractive target for further investigation. Further studies are needed to fully understand the role of SAMSMON in these processes and to determine its potential as a therapeutic drug.

Protein Name: Survival Associated Mitochondrial Melanoma Specific Oncogenic Non-coding RNA

The "SAMMSON Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SAMMSON comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets